BioRay Pharmaceutical
Blood & Organ Banks · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Shugang Road 1 Jiaojiang District, Taizh...Phone Number
+86 2021020262Website
www.bioraypharm.comRevenue
<$5 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
1
2
1
2
About BioRay Pharmaceutical
As a pioneer in China's biopharmaceutical industry, BioRay started the R&D of biologics treatments in 2019 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceutical group founded in 1956. In 2019, PAG, a leading Asia-focused private equity firm, acquired the control of BioRay with an investment of RMB3.8B (USD$540M for 58% ownership), marking one of the largest PE investment in Asia's biotechnology industry to date. yearsExplore more
BioRay Pharmaceutical Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioRay Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioRay Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Check out if BioRay Pharmaceutical is spiking on competitors!
Funding: Get notified immidiatlly once BioRay Pharmaceutical has new funding data
Congratulate Masked Content for being promoted to Masked Content at BioRay Pharmaceutical
BioRay Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on BioRay Pharmaceutical recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BioRay Pharmaceutical had a recent Job posting/layoffs
Product Launch: Get notified when BioRay Pharmaceutical launches new products
Recommended Actions
Find VP level buyers at BioRay Pharmaceutical
Find 3 more new buyers
Company Profile Activity
Activity Insights
BioRay Pharmaceutical is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
BioRay Pharmaceutical is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about BioRay Pharmaceutical.
BioRay Pharmaceutical Tech Stack
A closer look at the technologies used by BioRay Pharmaceutical
BioRay Pharmaceutical News & Media
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20-positive diffuse large B-cell lymphoma (DLBCL), was officially approved for marketing by the National Medical Products Administration (NMPA). In preclinical studies, Anruixi® showed stronger antibody-depBioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the...BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration (NMPA) (Acceptance No. CXSL2300366). LIV-1, also known as SLC39A6 or ZIP6, is a multi-pass transmembr
Read more news
Top Blood & Organ Banks Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioRay Pharmaceutical
Sign Up For FreeTo access detailed company insights
As a pioneer in China's biopharmaceutical industry, BioRay started the R&D of biologics treatments in 2019 as a core business division of Hisun Pharmaceutical, a specialty comprehensive pharmaceutical group founded in 1956. In 2019, PAG, a leading Asia-focused private equity firm, acquired the control of BioRay with an investment of RMB3.8B (USD$54... Read More
